Roche Holding AG (RHHVF)
| Previous Close | 299.20 |
| Open | 306.00 |
| Bid | 296.68 x 4000 |
| Ask | 324.30 x 3100 |
| Day's Range | 299.20 - 311.80 |
| 52 Week Range | 233.12 - 340.88 |
| Volume | |
| Avg. Volume | 8,675 |
| Market Cap | 255.527B |
| Beta (5Y Monthly) | 0.15 |
| PE Ratio (TTM) | 20.28 |
| EPS (TTM) | 15.59 |
| Earnings Date | Jul 25, 2024 |
| Forward Dividend & Yield | 10.86 (3.44%) |
| Ex-Dividend Date | Mar 14, 2024 |
| 1y Target Est | N/A |
- Yahoo Finance Video
JPMorgan initiates coverage on GLP-1 entrant Viking Therapeutics
JPMorgan initiates coverage on Viking Therapeutics (VKTX) with an Overweight rating and price target of $80 per share. Viking Therapeutics stock has jumped 10% on Wednesday, currently hovering above $60. Market Domination hosts Julie Hyman and Josh Lipton report on the analyst note, also noting Novo Nordisk's (NVO) and Roche's (ROG.SW, RHHBY) own plans for experimental obesity pills. In an August installment of Good Buy or Goodbye, RSE Ventures Co-Founder and CEO Matt Higgins told Yahoo Finance why he believes Viking Therapeutics will become a new leader in the GLP-1 weight-loss drug space. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
ReutersRoche shares knocked by concern over side effects in obesity pill trial
FRANKFURT (Reuters) -Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes was linked to an elevated rate of temporary side effects in its initial test phase on humans. Roche shares were trading 3.5% down by 0940 GMT, the second biggest faller on the pan-European STOXX 600 index, after the company presented details on the trial with once-daily pill CT-996 late on Wednesday. According to a presentation at a meeting of the European Association for the Study of Diabetes in Madrid, all 25 trial participants experienced mild or moderate side effects, or adverse events in industry parlance, including those that only received an ineffective placebo.
BloombergRoche Shares Drop on Concern About Obesity Pill Side Effects
(Bloomberg) -- Roche Holding AG’s shares slid the most in more than a month after its closely-watched experimental obesity pill was tied to side effects, raising questions about the drugmaker’s competitiveness in the hottest new pharmaceutical market.Most Read from BloombergHow Americans Voted Their Way Into a Housing CrisisFor Tenants, AI-Powered Screening Can Be a New Barrier to HousingAfter a Record Hot Summer, Pressure Grows for A/C MandatesChicago Halts Hiring as Deficit Tops $1 Billion Thr
